I am a
Home I AM A Search Login

Papers of the Week


2019 Dec 11


Trials


20


1

Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial.

Authors

Mondardini M C, Sperotto F, Daverio M, Caramelli F, Gregori D, Caligiuri M F, Vitale F, Cecini M T, Piastra M, Mancino A, Pettenazzo A, Conti G, Amigoni A
Trials. 2019 Dec 11; 20(1):710.
PMID: 31829274.

Abstract

Prolonged treatment with analgesic and sedative drugs in the pediatric intensive care unit (PICU) may lead to undesirable effects such as dependence and tolerance. Moreover, during analgosedation weaning, patients may develop clinical signs of withdrawal, known as withdrawal syndrome (WS). Some studies indicate that dexmedetomidine, a selective α2-adrenoceptor agonist, may be useful to prevent WS, but no clear evidence supports these data. The aims of the present study are to evaluate the efficacy of dexmedetomidine in reducing the occurrence of WS during analgosedation weaning, and to clearly assess its safety.